Skip to main content
Premium Trial:

Request an Annual Quote

Abbott Will Manufacture Human Thrombin for Zymogenetics

NEW YORK, Oct. 2 (GenomeWeb News) - Zymogenetics today said that Abbott Laboratories will manufacture its recombinant human trombin.

 

ZymoGenetics, which is developing rhThrombin as an alternative to bovine plasma-derived thrombin for use as a topical hemostat, expects to market the product at the end of 2006, a company spokeswoman told GenomeWeb News.

Plasma-derived thrombin has been used as a hemostatic agent for more than 30 years, and is applied topically to surgical incisions, sutures, and burn, according to Zymogenetics. Bovine thrombin is currently the only form of thrombin that is sold in the United Statesas a stand-alone product for the treatment of surgical bleeding, the company said.

 

"Recombinant coagulation proteins have so far been accepted by the medical community as safe alternatives to plasma-derived proteins, as demonstrated by the rapid acceptance of recombinant forms of coagulation Factor VIII and Factor IX," Zymogenetics said.

 

Zymogenetics is a Seattle-based spin-off of Novo Nordisk.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.